CTCBIO Inc (060590) - Net Assets

Latest as of September 2025: ₩71.75 Billion KRW ≈ $48.62 Million USD

Based on the latest financial reports, CTCBIO Inc (060590) has net assets worth ₩71.75 Billion KRW (≈ $48.62 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩149.18 Billion ≈ $101.10 Million USD) and total liabilities (₩77.43 Billion ≈ $52.47 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check financial resilience of CTCBIO Inc to evaluate the company's liquid asset resilience ratio.

Key Net Assets Metrics

Metric	Value
Current Net Assets	₩71.75 Billion
% of Total Assets	48.1%
Annual Growth Rate	3.45%
5-Year Change	-8.77%
10-Year Change	-29.78%
Growth Volatility	20.55

CTCBIO Inc - Net Assets Trend (2011–2024)

This chart illustrates how CTCBIO Inc's net assets have evolved over time, based on quarterly financial data. Also explore 060590 asset base for the complete picture of this company's asset base.

Annual Net Assets for CTCBIO Inc (2011–2024)

The table below shows the annual net assets of CTCBIO Inc from 2011 to 2024. For live valuation and market cap data, see market cap of CTCBIO Inc.

Year	Net Assets	Change
2024-12-31	₩69.62 Billion ≈ $47.18 Million	-7.72%
2023-12-31	₩75.44 Billion ≈ $51.13 Million	-21.38%
2022-12-31	₩95.96 Billion ≈ $65.03 Million	+12.88%
2021-12-31	₩85.01 Billion ≈ $57.61 Million	+11.40%
2020-12-31	₩76.32 Billion ≈ $51.72 Million	+2.11%
2019-12-31	₩74.74 Billion ≈ $50.65 Million	-13.97%
2018-12-31	₩86.87 Billion ≈ $58.87 Million	+17.42%
2017-12-31	₩73.98 Billion ≈ $50.14 Million	-18.61%
2016-12-31	₩90.89 Billion ≈ $61.60 Million	-8.32%
2015-12-31	₩99.14 Billion ≈ $67.19 Million	+15.97%
2014-12-31	₩85.49 Billion ≈ $57.94 Million	-7.30%
2013-12-31	₩92.23 Billion ≈ $62.50 Million	+47.80%
2012-12-31	₩62.40 Billion ≈ $42.29 Million	+39.23%
2011-12-31	₩44.82 Billion ≈ $30.37 Million	--

Equity Component Analysis

This analysis shows how different components contribute to CTCBIO Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

Retained earnings have decreased by 5538763021000.0% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (December 2024)

Component	Amount	Percentage
Common Stock	₩12.09 Billion	17.37%
Other Components	₩112.92 Billion	162.19%
Total Equity	₩69.62 Billion	100.00%

CTCBIO Inc Competitors by Market Cap

The table below lists competitors of CTCBIO Inc ranked by their market capitalization.

Company	Market Cap
Immutep Ltd AU:IMM	$62.49 Million
Garo AB ST:GARO	$62.52 Million
Manba Finance Ltd NSE:MANBA	$62.53 Million
Scherzer & Co. AG F:PZS	$62.54 Million
Cobre Ltd AU:CBE	$62.45 Million
PJ Metal Co. Ltd KQ:128660	$62.45 Million
THINKWARE Corporation KQ:084730	$62.44 Million
Dawson Geophysical Company NASDAQ:DWSN	$62.41 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in CTCBIO Inc's equity between the two most recent reporting periods.

Equity Growth Insights

From 2023 to 2024, total equity changed from 75,444,321,160 to 69,620,419,960, a change of -5,823,901,200 (-7.7%).
Net loss of 5,220,439,230 reduced equity.

Equity Change Factors (2023 to 2024)

Factor	Impact	Contribution
Net Income	₩-5.22 Billion	-7.5%
Other Changes	₩-603.46 Million	-0.87%
Total Change	₩-	-7.72%

Book Value vs Market Value Analysis

This analysis compares CTCBIO Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Current price-to-book ratio: 1.32x
The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
The price-to-book ratio has increased from 0.73x to 1.32x over the analyzed period, suggesting growing market confidence.

Historical Price-to-Book Ratios

Date	Book Value per Share	Market Price	P/B Ratio
2016-12-31	₩5283.66	₩3855.00	x
2017-12-31	₩4275.72	₩3855.00	x
2018-12-31	₩4563.01	₩3855.00	x
2019-12-31	₩3925.70	₩3855.00	x
2020-12-31	₩3673.67	₩3855.00	x
2021-12-31	₩3640.60	₩3855.00	x
2022-12-31	₩4013.72	₩3855.00	x
2023-12-31	₩3155.51	₩3855.00	x
2024-12-31	₩2911.92	₩3855.00	x

Capital Efficiency Dashboard

This dashboard shows how efficiently CTCBIO Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

Current Return on Equity (ROE): -7.50%
The company may be facing challenges in efficiently utilizing shareholder equity.
DuPont Analysis Breakdown:
• Net Profit Margin: -3.62%
• Asset Turnover: 0.94x
• Equity Multiplier: 2.21x
Recent ROE (-7.50%) is above the historical average (-7.87%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year	Return on Equity	Net Profit Margin	Asset Turnover	Equity Multiplier	Economic Value Added
2012	13.13%	6.31%	1.04x	2.01x	₩1.95 Billion
2013	0.94%	0.70%	0.82x	1.63x	₩-8.35 Billion
2014	-4.10%	-2.87%	0.75x	1.90x	₩-12.05 Billion
2015	2.76%	2.30%	0.61x	1.95x	₩-7.17 Billion
2016	-3.01%	-2.22%	0.65x	2.08x	₩-11.83 Billion
2017	-27.98%	-15.85%	0.68x	2.59x	₩-28.10 Billion
2018	-10.43%	-6.55%	0.72x	2.21x	₩-17.75 Billion
2019	-18.38%	-10.09%	0.73x	2.50x	₩-21.21 Billion
2020	-25.50%	-14.96%	0.73x	2.32x	₩-27.09 Billion
2021	-8.61%	-5.22%	0.83x	1.98x	₩-15.82 Billion
2022	7.04%	4.09%	0.88x	1.96x	₩-2.84 Billion
2023	-20.66%	-11.31%	0.83x	2.20x	₩-23.13 Billion
2024	-7.50%	-3.62%	0.94x	2.21x	₩-12.18 Billion

Industry Comparison

This section compares CTCBIO Inc's net assets metrics with peer companies in the Biotechnology industry.

Industry Context

Industry: Biotechnology
Average net assets among peers: $259,878,662,431
Average return on equity (ROE) among peers: -3.52%

Peer Company Comparison

Company	Net Assets	Return on Equity	Debt-to-Equity	Market Cap
CTCBIO Inc (060590)	₩71.75 Billion	13.13%	1.08x	$62.46 Million
ORIENTBIO Inc. (002630)	$62.29 Billion	1.41%	1.19x	$42.67 Million
Green Cross (005250)	$218.85 Billion	4.49%	0.86x	$424.80 Million
Green Cross Holdings Preference Shares (005257)	$1.85 Trillion	1.30%	0.98x	$3.72 Million
Pharmicell (005690)	$101.58 Billion	-17.37%	0.34x	$823.44 Million
GeneOne Life Science Inc (011000)	$181.47 Billion	-21.02%	0.23x	$48.33 Million
HLB Co. Ltd (028300)	$23.02 Billion	-12.73%	1.36x	$5.41 Billion
Daesung Microbiological Labs. Co. Ltd (036480)	$21.14 Billion	9.66%	0.31x	$18.95 Million
Seoulin Bioscience Co.Ltd (038070)	$51.49 Billion	4.00%	0.38x	$37.75 Million
Hyundai Bioscience Co. Ltd (048410)	$21.80 Billion	0.00%	0.41x	$937.21 Million
iNtRON Biotechnology Inc (048530)	$64.96 Billion	-4.91%	0.37x	$74.45 Million

About CTCBIO Inc

KQ:060590 Korea Biotechnology

Market Cap

$62.46 Million

₩92.17 Billion KRW

Market Cap Rank

#21017 Global

#1308 in Korea

Share Price

₩3855.00

Change (1 day)

-1.53%

52-Week Range

₩3620.00 - ₩7450.00

All Time High

₩18000.00